- November 14, 2008
- Ambrilia Reports Third Quarter 2008 Results
Ambrilia Biopharma
Ambrilia Biopharma Inc. (TSX:AMB) is a biotechnology company focused on the discovery and development of novel treatments for viral diseases and cancer. The Company's strategy aims to capitalize on its broad portfolio and original expertise in virology.
Ambrilia's product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a therapeutic peptide for prostate cancer, a targeted delivery technology for cancer, HIV protease, integrase and entry inhibitors, HCV entry and polymerase inhibitors and Anti-Influenza A compounds.
News
Events
Recent Events
- October 1 - 3, 2008

- BioContact Quebec 2008
Quebec City, Canada - September 23 - 24, 2008

- Sachs 8th Annual Biotech in Europe Investor Forum
Zurich, Switzerland - August 12 - 14, 2008

- Canaccord Adams 28th Global Growth Conference
Boston, USA - August 11, 2008

- Second Quarter 2008 Results

